(NASDAQ: OABI) Omniab's forecast annual revenue growth rate of 43.76% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 35.8%, and it is also forecast to beat the US market's average forecast revenue growth rate of 13.37%.
Omniab's revenue in 2026 is $18,666,000.On average, 9 Wall Street analysts forecast OABI's revenue for 2026 to be $4,119,211,090, with the lowest OABI revenue forecast at $3,613,050,956, and the highest OABI revenue forecast at $4,598,875,999. On average, 8 Wall Street analysts forecast OABI's revenue for 2027 to be $6,784,080,490, with the lowest OABI revenue forecast at $4,185,666,325, and the highest OABI revenue forecast at $11,874,059,228.
In 2028, OABI is forecast to generate $7,698,093,341 in revenue, with the lowest revenue forecast at $5,476,837,971 and the highest revenue forecast at $11,025,632,917.